Description:

Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H1, 2016” provides an overview of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial
Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

**Table Of Contents:**

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy to Oncology Clinical Trials 15
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, Europe, Top Five Countries, 2016* 11
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, North America, Top Countries, 2016* 12
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, Central and South America, Top Five Countries, 2016* 14
Proportion of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy to
Oncology Clinical Trials, G7 Countries (%), 2016* 16
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, G7
Countries, Clinical Trials by Phase, 2016* 17
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, G7
Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy to
Oncology Clinical Trials, E7 Countries (%), 2016* 20
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, E7
Countries, Clinical Trials by Phase, 2016* 21
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, E7
Countries, Clinical Trials by Trial Status, 2016* 22
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics,
Global, Clinical Trials by Phase, 2016* 23
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics,
Global, Clinical Trials In Progress by Phase 2016* 24
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics,
Global, Clinical Trials by Trial Status, 2016* 25
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, Global, by End Point Status, 2016* 26
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Market, Global, Clinical Trials by Sponsor Type, 2016* 28
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, Global, Key Sponsors, 2016* 30
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, Global, Top Companies by Phase, 2016* 32
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics
Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 33
List of Figures
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
Proportion of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy to Oncology Clinical Trials, E7 Countries (%), 2016* 19
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, Global, Clinical Trials by Phase (%), 2016* 23
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 24
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 28
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 31
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 33
GlobalData Methodology 172

Companies Mentioned:

Celgene Corporation
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
Novartis AG
Seattle Genetics, Inc.
Solasia Pharma K.K.
Amgen Inc.
Kirin Holdings Company, Limited
Johnson & Johnson
F. Hoffmann-La Roche Ltd.

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports
by providing full copyright credit to the publisher.

- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless an Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL: https://www.marketresearchreports.com/globaldata/angioimmunoblastic-t-cell-lymphoma-ailtimmunoblastic-lymphadenopathy-global-clinical-0

Links